« Previous
Next »
Titles
- CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid1
- CMS’s encounter data lack essential information that Medicare Advantage organizations have the ability to collect1
- COVID-19 intensifies nursing home workforce challenges1
- COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products : guidance for industry and investigators1
- COVID-19: brief update on initial federal response to the pandemic : report to Congress1
- COVID-19: federal efforts accelerate vaccine and therapeutic development, but more transparency needed on emergency use authorizations : report to Congressional addressees1
- COVID-19: federal efforts could be strengthened by timely and concerted actions : report to Congressional committees1
- COVID-19: opportunities to improve federal response and recovery efforts : report to the Congress1
- COVID-19: urgent actions needed to better ensure an effective federal response : report to Congressional committees1
- Cancer clinical trial eligibility criteria: brain metastases1
- Cancer clinical trial eligibility criteria: minimum age considerations for inclusion of pediatric patients : guidance for industry and IRBs1
- Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B Virus, or hepatitis C Virus Infections1
- Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies1
- Center for Devices and Radiological Health (CDRH) appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff1
- Certificates of confidentiality: guidance for sponsors, sponsor-investigators, researchers, industry, and food and drug administration staff1
- Changes in home health care use in Medicare Advantage compared to traditional Medicare: 2011--20161
- Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)1
- Civil money penalties relating to the ClinicalTrials.gov data bank: guidance for responsible parties, submitters of certain applications and submissions to FDA, and FDA staff1
- Classification of posterior cervical screw systems: small entity compliance guide : guidance for industry and Food and Drug Administration staff1
- Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions1